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ABSTRACT
Using the relative expression levels of two SNP
alleles of a gene in the same sample is an effective
approach for identifying cis-acting regulatory SNPs
(rSNPs). In the current study, we established a
process for systematic screening for cis-acting
rSNPs using experimental detection of AI as an
initial approach. We selected 160 expressed candi-
date genes that are involved in cancer and anti-
cancer drug resistance for analysis of AI in a panel
of cell lines that represent different types of cancers
and have been well characterized for their response
patterns against anticancer drugs. Of these genes,
60 contained heterozygous SNPs in their coding
regions, and 41 of the genes displayed imbalanced
expression of the two cSNP alleles. Genes that
displayed AI were subjected to bioinformatics-
assisted identification of rSNPs that alter the
strength of transcription factor binding. rSNPs in
15 genes were subjected to electrophoretic mobility
shift assay, and in eight of these genes (APC, BCL2,
CCND2, MLH1, PARP1, SLIT2, YES1, XRCC1)w e
identified differential protein binding from a nuclear
extract between the SNP alleles. The screening
process allowed us to zoom in from 160 candidate
genes to eight genes that may contain functional
rSNPs in their promoter regions.
INTRODUCTION
Single nucleotide polymorphisms (SNPs) in genomic
regions that regulate gene expression are major causes
of human diversity and may also be important suscep-
tibility factors for complex diseases and traits. Several
studies have used linkage or association analysis with
microarray-based expression data from lymphoblastoid
cell-lines from healthy individuals as the quantitative trait,
and have identiﬁed putative cis- and trans-acting genetic
variants that regulate the gene expression levels (1–4). So
far only a few studies have addressed the relationship
between SNPs in regulatory regions of multiple genes and
gene expression levels in human diseases in a systematic
way. A recent exception is a study, in which the
association between SNPs in 200 candidate genes was
analyzed against gene expression levels determined using
cDNA arrays in breast cancer tumor samples (5). Using
novel statistical tools, this study of 50 tumor samples
identiﬁed both cis- and trans-acting putative regulatory
SNPs (rSNPs).
To use the relative expression levels of two SNP alleles
(allelic imbalance (AI)) of a gene in the same sample,
instead of the total expression level as the quantitative
phenotype is an alternative approach for identifying cis-
acting rSNPs or haplotypes (6–10). A major advantage of
this approach is that the two SNP alleles are measured in
the same environment, and serve as internal standards for
each other to control other than cis-acting genetic factors
and environmental factors that may cause diﬀerences in
the expression levels between samples. AI in expression
has proven to be a common phenomenon for human
genes. One study detected AI in the expression of 326 out
of 602 human genes (54%) by using Aﬀymetrix HuSNP
oligonucleotide arrays to study kidney and liver tissues
from seven fetuses (11). By analyzing leukocytes from
12 individuals using allele-speciﬁc oligonucleotide hybri-
dization arrays (Perlegen Sciences) another study found
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In addition to allele-speciﬁc hybridization on microarrays,
a variety of other genotyping methods have been applied
to detect AI (6–8,13–15). Due to variation in the
sensitivity and speciﬁcity of the methods, and the limited
number of samples or SNPs included in these studies, the
frequency estimates for AI vary largely between studies,
from 18 to 60% of the analyzed genes. Imbalanced
expression of alleles has also been detected using
bioinformatics tools, comparing the allele frequencies of
SNPs in expressed sequence tags (ESTs) databases to
the allele frequencies in Centre d’Etude du Polymorphisme
Humain (CEPH) samples from the Haplotype Mapping
project (16). This study estimated that AI occurred for
36% of over 2500 analyzed genes, and AI was experi-
mentally veriﬁed for 40 of the genes by sequencing.
In the current study, we established a process for
systematic screening for cis-acting rSNPs using experi-
mental detection of AI as an initial approach. An
approach with similar steps as in our study, but performed
in a diﬀerent order than in our process, was recently
described for identifying rSNPs that are associated with
osteoarthritis (7). Inspired by a number of studies that
have identiﬁed putative rSNPs in genes related to cancer
(14,17,18) and the response to treatment with anticancer
drugs (19–22), we used a panel of cell lines that represent
diﬀerent types of cancers and have been well characterized
for their response patterns against anticancer drugs (23)
as target cells in our study. For detecting AI in the
expression of candidate genes for cancer and anticancer
drug response we used our ‘in house’ developed
tag-microarray minisequencing system, which we have
previously shown to be accurate and sensitive for
quantitative detection of AI (15). Genes that displayed
AI were then subjected to bioinformatics-assisted identi-
ﬁcation of rSNPs that alter the strength of transcription
factor binding in their upstream regulatory regions. The
putative rSNPs were tested for their protein-binding
capacity using electrophoretic mobility shift assays
(EMSAs). This process allowed us to zoom in from the
160 originally selected candidate genes to eight genes that
might contain rSNPs that aﬀect the transcription levels of
the genes.
MATERIALS AND METHODS
Celllines
A panel of 13 human tumor cell-lines consisting of drug-
sensitive parental cell-lines and resistant subtypes was
analyzed. Table 1 presents a summary of the cell lines,
including their origin, parental cell-lines and the resistant
subtypes and the selecting agents used to create resistant
subtypes. The cell-line cultures have regularly been
monitored and found negative for mycoplasma contam-
ination. The cell lines have been described in detail by
Dhar et al. (23).
Extraction ofDNA, RNA andcDNA synthesis
Genomic DNA was extracted from the 13 cell-lines
using the Genelute
TM Mammalian Genomic DNA kit
(Sigma, St. Louis, MO, USA), and the DNA was stored at
–208C until use. Total RNA was extracted by a standard
guanidine isothiocyanate method (TRIZOL Reagent;
Gibco BRL/Invitrogen). The quality of the RNA was
veriﬁed by running the samples on a 1% agarose gel,
and the RNA was quantiﬁed by measuring the
ultraviolet absorbance at 260 and 280nm (NanoDrop
Technologies). Twenty micrograms of RNA was treated
with DNase I to remove genomic DNA using the RNeasy
Mini Kit (Qiagen, 74104). Adequate removal of the
genomic DNA after DNase I treatment was veriﬁed by
absence of PCR products from RNA samples using
primers for genomic DNA. Five micrograms of puriﬁed
RNA was reverse transcribed to cDNA using the
High-Capacity cDNA archive kit (Applied Biosystems,
4322171).
Gene expression profiling
The expression levels of 7400 genes in 13 of the parental
and drug-resistant cell-lines had been previously deter-
mined using mRNA expression microarrays with cDNA
probes (24). Twelve of the cell lines were selected to
represent all cancer types in expression proﬁling on
Sentrix Genome-Wide Expression BeadChips (Illumina
Inc., San Diego, CA, USA). Biotinylated cRNA was
prepared from 500ng of RNA, using the TotalPrep
TM
RNA Labeling Kit (Ambion). The in vitro transcription
product was puriﬁed and labeled with Cy3-labeled
streptavidin, followed by overnight hybridization of
1.5mg of the labeled product to the BeadChips.
The following day, the slides were washed and scanned
using a Bead Station GX 500 Array Reader (Illumina Inc.,
San Diego, CA, USA). The image data ﬁles were analyzed
using the BeadStudio software (Illumina Inc., San Diego,
CA, USA), where the ‘rank invariant’ normalization
model was applied, as recommended by the manufacturer.
The limit of detection was set at 98% conﬁdence.
PCR
Primers for PCR and minisequencing primers with
20-nucleotide tag sequences were designed using the
Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/pri
mer3.cgi) and Autoprimer (http://www.autoprimer.com)
(Beckman Coulter) softwares. The primers were obtained
from Integrated DNA Technologies (IDT Inc., Coralville,
Table 1. Summary of cell lines analyzed
Parental CL Resistant CL Origin Selecting agent
8226/S 8226/Dox Myeloma Doxorubicin
8226/LR5 Myeloma Melphalan
CCRF-CEM CEM/VM-1 T-cell leukemia Teniposide
NCI-H69 H69AR Small cell lung cancer Doxorubicin
U937-GTB U937/VCR Histiocytic lymphoma Vincristine
GTB/CHS Histiocytic lymphoma Cynoguanidine
HELA   Cervical cancer
HTERT   Normal epithelial retina
ACHN   Renal adenocarcinoma
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ampliﬁed by PCR from genomic DNA in multiplex
reactions with 6–12 amplicons per reaction, using 10ng
of DNA, 0.1mM dNTPs, 1 U Smart-Taq hot DNA
polymerase (Naxo Ltd., Tartu, Estonia), 4mM MgCl2 and
0.2mM of primers in a ﬁnal volume of 30ml. PCR from
cDNA was performed in individual reactions using 1/20 of
the cDNA products, 0.1mM dNTPs, 0.5 U Smart-Taq hot
DNA polymerase, 1.5mM MgCl2 and 0.2mM of primers
in a ﬁnal volume of 30ml. The PCR conditions were initial
activation of the enzyme at 958C for 10min followed by 40
cycles of 958C for 1min, 558C for 30s and 728C for 1min
in a Thermal Cycler PTC225 (MJ Research, Watertown,
MA, USA). The ampliﬁed cDNA fragments were pooled
and concentrated to 40ml using Microcon YM-30
Centrifugal Filter Devices (Millipore Corporation,
Bedford, MA, USA).
Preparation of microarrays
Oligonucleotides that were complementary to the tag
sequences on the minisequencing primers were immobi-
lized covalently on CodeLink
TM Activated Slides (GE
Healthcare, Uppsala, Sweden) by the mediation of a
NH2-group at their 30-end as described earlier (25).
Each oligonucleotide was applied as duplicate spots to
the slides at a concentration of 25mM in 150mM sodium
phosphate pH 8.5 using a ProSys 5510A instrument
(Cartesian Technologies Inc., Irvine. CA, USA) equipped
with four Stealth Micro Spotting pins (SMP3B,
TeleChem International Inc., Sunnyvale, CA, USA). The
oligonucleotides were spotted in an ‘array-of-arrays’
conﬁguration, which facilitates analysis of 80 individual
samples in parallel on each microscope slide. In each
‘subarray,’ a ﬂuorophore-labeled oligonucleotide was
included as a control for the immobilization process.
After printing, the slides were incubated in a humid
chamber for at least 24h, followed by treatment with
ethanolamine. The slides were stored desiccated in the
dark until use.
Tag-microarray minisequencing
Excess of PCR primers and dNTPs was removed by
treatment of the PCR mixtures with 5 U of Exonuclease I
and 1 U of shrimp alkaline phosphatase (USB
Corporation, Cleveland, OH, USA). Multiplex cyclic
minisequencing primer extension reactions were per-
formed in the presence of 80 tagged primers in both
DNA polarities at 10nM concentration, 0.1mM Texas
Red-ddATP, Tamra-ddCTP, R110-ddGTP and 0.15mM
Cy5-ddUTP (Perkin Elmer Life Sciences, Boston, MA,
USA) and 0.065 U of KlenThermase
TM DNA polymerase
(GeneCraft, Germany), as described earlier (26).
Alternatively, reagents from the SNPstream genotyping
system (Beckman Coulter, Fullerton, California, USA)
were used for the cyclic minisequencing reaction.
A reference oligonucleotide that is complementary to
a synthetic template to mimic a four-allelic SNP was
added to the minisequencing reaction to monitor the
diﬀerence in incorporation eﬃciency of the four nucleo-
tides by the DNA polymerase. The reaction conditions
were initial activation of the enzyme at 968C for 5min
followed by 33 cycles of 95 and 558C for 20s each.
The extension products were allowed to anneal to the
immobilized complementary tag oligonucleotides at 428C
for 1–2h followed by washing of the slide with 2 SSC
and 0.1% SDS twice for 5min at 428C and twice with
0.2 SSC for 1min at room temperature. Five replicates
of DNA and cDNA from the same cell-line were analyzed
in parallel.
Signal detection and dataanalysis
Fluorescence was measured from the microarrays using a
ScanArray Express instrument (Perkin Elmer Life
Sciences, Boston, MA, USA) with the excitation lasers
Blue Argon 488nm (R110 and ﬂuorescin), Green HeNe
543.8nm (Tamra), Yellow HeNe 594nm (Texas Red)
and Red HeNe 632.8nm (Cy5) with the laser power set
to 88% and the photomultiplier tube gain adjusted
to obtain equal signal intensities from the reaction
control for all ﬂuorophores. The ﬂuorescence signals
were quantiﬁed using the QuantArray analysis
3.1 software (Perkin Elmer Life Sciences, Boston,
MA, USA).
The SNP genotypes were assigned using the
SNPsnapper software v3.0.0.191 (http://www.bioinfo.
helsinki.ﬁ/SNPSnapper/) based on scatter plots with the
logarithm of the sum of both ﬂuorescence signals
(SAllele1þSAllele2) on the vertical axis and the ﬂuorescence
signal fractions [SAllele2/(SAllele1þSAllele2)] on the horizon-
tal axis. The genotypes together with the signal intensities
of the incorporated nucleotides were exported to
Microsoft Excel. The data was handled and interpreted
using the Microsoft Excel and Access programs. AI was
determined by calculating the ﬂuorescence signal ratio
between the two alleles (SAllele1/SAllele2) in cDNA and
DNA for each heterozygous SNP. The signal ratio from
cDNA was divided by the corresponding ratio in DNA to
obtain a measure for AI. In this calculation, the mean
signal intensity of duplicate spots in one sub-array was
considered as one replicate assay, and ﬁve replicate assays
were performed for each SNP. A two-tailed student’s t-test
was used to calculate the signiﬁcance of the diﬀerence in
the allelic ratios for the SNPs in genomic DNA and cDNA
(Figure 1).
Analysisof regulatory regions affected by SNPs
The bioinformatics tool Regulatory Analysis of Variation
in Enhancers (RAVEN) (M. Andersen, B. Lenhard et al.,
in preparation) was used for the identiﬁcation of potential
rSNPs in the promoter regions of the genes with
imbalanced expression. RAVEN (http://mordor.cgb.
ki.se/CONSNP/) combines position weight matrices for
transcription factor binding sites (TFBSs) from the
manually curated Jaspar database (27,28) with phyloge-
netic footprinting to increase the likelihood of identifying
functional variants. The RAVEN interface enables auto-
matic analysis of SNPs from dbSNP as well as uploading
of additional SNPs. Based on the application of position-
speciﬁc weight matrices, RAVEN gives a score that ranges
from 1 to 15 for binding sites of 6–14 nucleotides in length
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MAF 40.05 were selected for further genotyping by
applying a minimum SNP-caused score diﬀerence over 2
between the high- and low-scoring SNP alleles in the
TFBS proﬁle and a conservation cut-oﬀ above 70%
between human and mouse, based on the phylogenetic
footprinting.
Electrophoretic mobility shiftassays (EMSA)
Complementary double-stranded 50 biotinylated as well as
unmodiﬁed 30bp oligonucleotides, containing the
predicted TFBS, were designed for each allele of putative
rSNPs (Table 2). The oligonucleotides were obtained from
Integrated DNA Technologies (IDT Inc., Coralville, IA,
USA). The complementary oligonucleotides were allowed
to anneal in 10mM Tris–HCl, pH 7.5, 50mM NaCl,
1mM EDTA to generate double-stranded probes for the
EMSA reaction. Twenty femtomoles of the labeled
double-stranded probes were incubated with 5mgo f
HELA or Jurkat nuclear extracts (Active Motif, Carlsbad,
CA, USA) in a freshly made binding buﬀer containing
12mM HEPES pH 7.4, 5mM MgCl2, 60mM KCl, 1%
glycerol, 0.05% NP-40, 50mg/ml BSA, 1mM DTT,
0.5mM EDTA with 50ng/ml of poly(dI-dC) poly(dI-dC)
(Amersham Biosciences, Piscataway, NJ, USA) and
Halt
TM Protease Inhibitor Cocktail (Pierce
Biotechnology, Rockford, IL, USA) in a ﬁnal volume of
20ml. Three reactions were prepared for each double-
stranded oligonucleotide (see Figure 2). The mixtures were
incubated at room temperature for 20min, and analyzed
using electrophoresis on 6% polyacrylamide gels
(Bio-Rad Laboratories, Hercules, CA, USA). The gels
were run for 1.5h at 100V, followed by transfer to
Hybond-Nþ nylon membranes (Buckinghamshire,
England) in 0.5 TBE for 1h at 550mA, using a
Criterion Blotter (Bio-Rad Laboratories, Hercules, CA,
USA). The LightShift Chemiluminescent EMSA kit
(Pierce Biotechnology, Rockford, IL, USA) was used to
visualize the biotinylated oligonucleotide signals on
the membranes and a ChemiDoc XRS system (Bio-Rad
Laboratories, Hercules, CA, USA). The EMSA
experiments were performed twice with reproducible
results.
Figure 1. Volcano plot of the AI data from 105 heterozygous cSNPs in
13 cell lines. AI for each SNP was determined by calculating the
ﬂuorescence signal ratio between the two alleles (SAllele1/SAllele2)i n
RNA (cDNA) and genomic DNA for each heterozygous SNP.
The level of AI obtained by dividing the signal ratio in RNA by
the corresponding ratio in DNA is plotted on the horizontal axis. The
P-value for the diﬀerence between allelic ratios in RNA and DNA
based on ﬁve replicate assays is plotted on the vertical axis. Spots above
the horizontal dashed line represent the SNPs showing AI at a
P-value50.0001 that were selected for further analysis.
Table 2. Result from validation of the transcription factor binding sites predicted by RAVEN by electrophoretic mobility shift assays
Gene
a SNP
b EMSA probes (one strand)
c Transcription factors
d Conﬁrmed by EMSA
e
APC rs2439591 GAAATCCATTACACAGAATAAGGCAGACA AGL3, E4BP4, HLF, SOX17, þ
GAAATCCATTACACAAAATAAGGCAGACA SQUA
BCL2 rs1944423 TTCATAAACTTGGAGAATATTTATATTGA Athb-1, HFH-1, HFH-2, HFH-3, –
TTCATAAACTTGGAGAACATTTATATTGA HNF-3beta, MEF2, SOX17
CCND2 rs3812821 ACCAGAACAACGTCCCTTGTGCCCCCCCC SOX17 –
ACCAGAACAACGTCCCTTCTGCCCCCCCC
MLH1 rs3172297 ATTTAAGACTATATGAATCAGAATTTTAA CF2-II þ
ATTTAAGACTACATGAATCAGAATTTTAA
PARP1 rs1317170 CTCGATGGGGTGCATGACATACACAGGATA CREB, bZIP910 þ
CTCGATGGGGTGCATAACATACACAGGATA
SLIT2 rs564041 ACCTAAAATCTCTGCAATATTCTCATTAA SOX17 þ
ACCTAAAATCTCTGCAATATCCTCATTAA
XRCC1 rs12608635 CGGCGGCGGGGAGCAGGTGCCACGGCCAAA Chop-cEBP, bZIP911 þ
CGGCGGCGGGGAGCAGGTGCCATGGCCAAA
YES1 rs7233932 GGAGCGCTCCGATTGTGCCCCTCTGCCTT SOX17, Sox-5 þ
GGAGCGCTCCGATTCTGCCCCTCTGCCTT
aGene symbol according to the HUGO gene nomenclature committee http://www.gene.ucl.ac.uk/nomenclature/
bThe SNPs rs8073706, rs907187, rs8176077, rs5016499, rs7655084, rs2717701 and rs3810378 in the respective ABCC3, PARP1, BRCA1, DCTD,
SLIT2, TNFRSF12A and XRCC1 genes were not conﬁrmed by EMSA.
cEMSA probe containing the SNP, the top probe contains the SNP allele that is predicted to give stronger transcription factor binding.
dTranscription factors predicted by RAVEN to bind to the probes.
eThe probes for the SNP alleles giving a stronger signal in EMSA that matched the predictions by RAVEN.
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Selection ofcandidate genesand coding SNPs
A panel of 13 human tumor cell-lines that includes drug-
sensitive parental cell-lines and their corresponding
resistant subtypes was analyzed to detect AI in the
expression of candidate genes involved in cancer progres-
sion and response to anticancer drugs (Table 1). These cell
lines have previously been well characterized for their
response patterns against 66 diﬀerent anticancer drugs
(23,24). Initially, we selected a panel of 210 candidate
genes for our study. The panel included oncogenes and
tumor suppressor genes selected from the literature
and genes relevant for the pathways of nine anticancer
drugs (irinotecan, 5-ﬂuorouracil, platinum, taxanes,
methotrexate, topotecan, gemcitabine, cyclophosphamide
and doxorubicin) according to the Pharmacogenetics
and Pharmacogenomics knowledge base website
(http://pharmacogenetics.wustl.edu/). Based on expression
data for 7400 human genes using cDNA microarrays (24)
and expression proﬁling using bead arrays with probes
for 46,000 transcripts (Illumina Inc.) (Milani et al.,
unpublished results), 160 of the 210 genes appeared to
be expressed in at least one of the cell lines (see
Supplementary Table 1). By searching the dbSNP and
Ensembl databases, we identiﬁed 237 SNPs with minor
allele frequencies above 10% in the coding region of the
expressed candidate genes.
Detectionof allelic imbalance
Next, we genotyped the cSNPs by multiplex tag-
microarray minisequencing in genomic DNA from the
cell lines and found that 79 of the candidate genes
contained coding SNPs (cSNPs) that were heterozygous in
at least one of the cell lines. These heterozygous cSNPs
Figure 2. Electrophoretic mobility shift assay images for the SNP alleles of the APC, BCL2, SLIT2, CCND2, XRCC1, PARP1, MLH1 and YES1
genes. Three lanes are shown for each SNP allele. From left to right these are: a control reaction with labeled probe only, a reaction containing both
labeled probe and nuclear extract and a reaction where an unlabeled probe is added in excess as a competitor, in addition to the labeled probe and
nuclear extract. For the MLH1 and YES1 genes, the two lanes are shown: a reaction with labeled probe and nuclear extract and a reaction where the
unlabeled competitor probe is added. The sequences of the allele-speciﬁc EMSA probes are given in Table 2.
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genomic DNA and RNA (cDNA) from the relevant cell
lines. Genotyping of the RNA samples was successful for
105 cSNPs in 60 genes. For 19 genes, genotyping assays
that were successful for genomic DNA failed in cDNA,
presumably due to the low expression level of these genes.
AI between the expressed alleles was initially observed by
aberrant clustering of the genotype data from RNA
compared to data from DNA in scatter plots. To obtain a
quantitative measure for the observed AI, the ﬂuorescence
signal (S) ratio between the two alleles (SAllele1/SAllele2)i n
RNA was divided by the corresponding signal ratio in
DNA for each SNP. A student’s t-test was then used
to assess the signiﬁcance of the diﬀerence between
allelic ratios in DNA and RNA based on ﬁve replicate
measurements. The ‘volcano plot’ in Figure 1 displays
the AI data from all 105 cSNPs and 13 cell lines with the
magnitude of AI plotted on the horizontal axis and the
P-values for the diﬀerences in signal ratios for the detected
AI on the vertical axis. The complete data underlying
Figure 1 is provided in Supplementary Table 2. Using a
conservative P-value of 0.0001 as signiﬁcance threshold we
detected AI in the expression of 41 of the genes (Table 3).
Figure 3 summarizes the recovery of genes at the diﬀerent
stages of our screening process.
Despite the conservative approach for deﬁning AI, the
relative number of genes that displayed AI in our study
(68%) was higher than that previously observed by others
based on screening with allele-speciﬁc hybridization
microarrays (11,12). The reason for this diﬀerence could
be the high sensitivity of detecting minority alleles using
minisequencing primer extension, which we have pre-
viously shown to be 1–5%, depending on the sequence
context of the SNP (15,29). Alternatively it is possible that
cancer-related genes in cancer cells are more frequently
expressed in an allele-speciﬁc manner than randomly
selected genes in lymphoblastoid cell-lines that have been
analyzed for AI in other studies.
As can be seen in Supplementary Table 2 the level of AI
that we measured in our study varied largely, from
1.3-fold (44% of the minor allele expressed) to over
40-fold (2.4% of the minor allele expressed). For a subset
of 15 genes we observed apparent monoallelic expression
in at least one of the cell lines, based on an allelic ratio in
RNA that was indistinguishable from a homozygous
genotype. Extreme AI, or monoallelic expression could, in
addition to a strong cis-acting regulatory eﬀect, be due to
lack of transcription of one allele because of methylation
of the promoter region as a consequence of imprinting.
In accordance with this notion, we have detected
methylation in the CpG islands in the 50 region of the
ERBB2 gene in the CCRF-CEM and CEM-VM1 cells that
showed monoallelic expression in the current study, but
not in HELA cells that displayed equal expression of the
ERBB2 alleles (Milani et al., unpublished results).
Eleven of the genes that displayed AI in our study
contained more than one heterozygous cSNP
(Supplementary Table 2). For example, SNPs rs12917
and rs1803965 in exon 3 of MGMT yielded 2.3-fold and
1.7-fold AI, respectively, in the CCRF-CEM cell line, and
no AI in any of the other cell lines. Three SNPs in diﬀerent
exons of PARP1 (rs1136410, rs1805404, rs3219061) all
yielded 2.3–2.9 fold AI in the HTERT cell line. This data
supports that our system yields reproducible results. On
the other hand, SNP rs602990 in exon 20 of VAV2
displayed 12-fold AI, while both alleles of SNP rs509590
in the 30 UTR of VAV2 were expressed at equal levels.
These apparently discordant results could be caused by
diﬀerential expression of alternatively spliced transcripts,
where the exon containing one of the SNPs has been
removed from one of the splice variants. Hence, measure-
ment of AI using SNPs distributed over diﬀerent exons
could be used for relative quantiﬁcation of alternatively
spliced transcripts, as an alternative approach to assays
based on detection of exon-speciﬁc nucleotides only
(29,30). AI could thus be used as a guide to SNPs that
regulate alternative splicing, analogously to the process
for identifying rSNPs that aﬀect the expression of the
entire transcript.
Bioinformatics-assisted identification ofSNPs that cause
allelic imbalance
Next, we attempted to identify SNPs in the 50-regulatory
regions of the 41 genes that displayed AI. For this
purpose, we used the RAVEN application. RAVEN
reports evolutionary conserved regions based on the
human and mouse genome sequences and scans the
sequences for the presence of potential TFBSs that are
aﬀected by SNPs. We used RAVEN to scan 3–5kb of the
50-regulatory regions of the 41 genes that were found to
display AI, and selected about 100 putative rSNPs in the
genes based on this analysis. The putative rSNPs identiﬁed
using RAVEN were subsequently genotyped in all the cell
lines (data not shown). The 15 rSNPs that were hetero-
zygous in the same samples as the originally genotyped
cSNPs in the corresponding genes were selected for further
analysis.
Functional analysis ofrSNPs
Fifteen of the rSNPs predicted by RAVEN and that
appeared to be in linkage disequilibrium (LD) with the
initially genotyped cSNP were analyzed for their capacity
to bind transcription factors or other proteins from a
nuclear cell extract by EMSAs (31,32). Allelic pairs of
eight of these SNPs that are located in the promoter
regions of the APC, BCL2, SLIT2, CCND2, XRCC1,
PARP1, MLH1 and YES1 genes displayed a reproducible
signal intensity diﬀerence in a product with altered
mobility in EMSA. Protein binding to only one of the
SNP alleles can be seen for the APC, BCL2 and XRCC1
genes, while for the SLIT2, CCND2, PARP1, MLH1 and
YES1 genes a diﬀerence in the amount of protein bound is
seen(Figure2). For as many as six of the SNPs, the allele
that showed stronger protein binding had been predicted
by RAVEN to have a stronger binding aﬃnity for a
transcription factor. The transcription factors predicted
to bind to the binding sites containing the rSNPs are
listed in Table 2. No protein binding or allele-speciﬁc
diﬀerences in binding were detectable using EMSA for
the remaining seven SNPs that are located in the
ABCC3, PARP1, BRCA1, DCTD, SLIT2, TNFRSF12A
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tool for enriching functional SNPs in TFBSs, although
ﬁne-tuning of the parameters of RAVEN as well as
raising the cut-oﬀ for detecting AI could increase its
success rate.
The genes in which we identiﬁed rSNPs were mainly
genes involved in cancer progression. BCL2 (the B-cell
CLL/lymphoma 2 gene), has been reported to be over-
expressed in diﬀerent leukemias and to be involved in
leukemogenesis (33) and the expression of TNFRSF12A
(the tumor necrosis factor receptor superfamily, member
12A gene) is important in cells undergoing apoptosis (34).
The Yamaguchi sarcoma viral oncogene homolog 1
(YES1) gene has been shown to be diﬀerentially expressed
in colon cancer cells treated with histone deacetylase
inhibitors (35). ABCC3, which encodes the multi-drug
resistance-associated protein 3, has been reported to be
involved in resistance to doxorubicin (36). The identiﬁed
rSNPs in these genes should be further validated by
functional assays. The genes and rSNPs identiﬁed in our
study are promising candidates for genetic association
studies with samples from patient cohorts with relevant
types of cancer or drug response patterns.
CONCLUSION
By the screening process presented here, we detected AI in
the expression levels of 41 out of 160 candidate genes that
were expressed in cancer cells, and applied AI as a guide to
putative rSNPs in these genes. Using bioinformatics tools
that predict TFBSs, we selected SNPs in the 50-regulatory
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Figure 3. Recovery of genes and SNPs at the diﬀerent stages of our
process for screening for allelic imbalance.
e34 Nucleic Acids Research, 2007, Vol. 35, No. 5 PAGE8 OF 10regions of genes for which AI was detected. We identiﬁed
rSNPs that had a suggestive allele-speciﬁc eﬀect, which
was shown experimentally by EMSA for eight genes. We
conclude that a screening process, such as the one
established in our study, that combines allele-speciﬁc
gene expression analysis with powerful bioinformatics
tools oﬀers a shortcut for the detection of potential cis-
acting regulators of gene expression. The process allows a
substantial reduction of the number of candidate rSNPs to
be subjected to labor-intensive genetic association or
functional studies.
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